Panavance Therapeutics is developing misetionamide (GP-2250), a tumor-cell selective agent that disrupts cancer cell metabolism and inhibits oncogenic transcription factors, targeting ovarian and pancreatic cancers. This approach addresses the unmet medical need for effective treatments in these cancer types by promoting cancer cell death and limiting tumor growth.
Funding
Funding not disclosed
Founders
Product
Problem
Ovarian and pancreatic cancers have limited effective treatment options, creating an unmet medical need for therapies that can effectively target and eliminate cancer cells. Current treatments often fail to completely eradicate tumors or prevent their recurrence.
Solution
Panavance Therapeutics is developing misetionamide (GP-2250), a tumor-cell selective agent designed to disrupt cancer cell metabolism and inhibit oncogenic transcription factors, specifically targeting ovarian and pancreatic cancers. Misetionamide selectively disrupts the energy metabolism of cancer cells, leading to cancer cell death. It also impacts nuclear factor-κB (NFκB), which affects cancer cells' ability for protein synthesis and DNA transcription, thereby restricting cancer cell growth and proliferation. Preclinical studies have demonstrated that misetionamide also suppresses pro-inflammatory cytokine production and inhibits c-MYC, potentially enhancing immunotherapy effectiveness.
Target Audience
The primary target audience includes patients with ovarian and pancreatic cancers, as well as oncologists seeking new and effective treatment options for these conditions.
Features
- Selectively disrupts cancer cell metabolism, leading to cancer cell death.
- Inhibits NFκB, restricting cancer cell growth and proliferation.
- Demonstrates pro-inflammatory cytokine suppression in preclinical studies.
- Inhibits c-MYC, potentially enhancing immunotherapy effectiveness.
- Demonstrated significant anti-cancer activity in numerous established and primary cell lines in preclinical research.